Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics announced a groundbreaking study using optical genome mapping (OGM) to identify structural variants (SVs) related to Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, affecting 1 in 4,500 females. The study analyzed samples from 87 MRKH patients and 47 parents, confirming the presence of 14 rare SVs in 19.5% of probands, and additional SVs in 27.6%. OGM demonstrated higher resolution and sensitivity than traditional methods, with significant findings including the first report of a MRKH patient with mosaicism for trisomy 12. This research may enhance understanding and treatment options for MRKH, a syndrome impacting female reproductive health.
Bionano Laboratories expanded its clinical testing menu by launching two new laboratory developed tests (LDTs) based on optical genome mapping (OGM): OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. The Postnatal test assesses structural variants in individuals with conditions like autism spectrum disorder and epilepsy, while the Prenatal test is for fetuses suspected of genetic anomalies. Both tests aim to provide comprehensive genome-wide assessments, assisting clinicians in patient management. The company emphasizes that these tests may facilitate OGM adoption in clinical and research settings.
Bionano Genomics (BNGO) announced its involvement in the ACMG Annual Meeting 2023, showcasing the significance of optical genome mapping (OGM) in genetics. CEO Dr. Erik Holmlin will present at the awards ceremony on March 15, alongside Dr. Bruce Korf, to honor LGG award recipients. The conference will feature key sessions on OGM's utility in detecting structural variants and its application in prenatal and postnatal analysis. Notable research presentations will include comparisons of OGM to traditional methods. The event highlights Bionano's commitment to advancing genetic disease research and supporting future leaders in the genomics field.
Bionano Genomics reported Q4 2022 revenue of $8.2 million, a 30% increase from Q4 2021. The total revenue for 2022 reached $27.8 million, marking a 55% increase over 2021. The company installed 240 Saphyr® systems by year-end, a 46% rise from 2021. Key validations showing optical genome mapping's (OGM) effectiveness for prenatal and postnatal genetic disorders were published. Full-year 2023 revenue is forecasted between $35 million and $38 million, indicating growth of 26% to 37% from 2022. However, operating expenses surged, with Q4 2022 GAAP operating expenses at $39.3 million.
Bionano Genomics (BNGO) announced two publication results from its clinical trial evaluating optical genome mapping (OGM) for diagnosing genetic disorders in postnatal patients. The peer-reviewed study revealed a 99.5% concordance rate of OGM against standard care methods and a 90.2% first-pass success rate. A subsequent preprint further confirmed a 99.6% overall concordance with 560 additional samples. Notably, OGM showed a 42% increase in reportable findings for genetic disorders and a 32% increase for autism spectrum disorders. The findings position OGM as a potential standard in genetic diagnosis, offering improved efficiency and accuracy.
Bionano Genomics, Inc. (BNGO) will host a conference call on March 9, 2023, at 4:30 p.m. EST to discuss its financial results for Q4 and year-end 2022, alongside recent corporate achievements. Interested participants can join via a live webcast on the company's investor page or by registering for a dial-in number and passcode.
For those unable to attend live, a replay will be available on the investor relations website for at least 30 days. Bionano is focused on advancing genomic solutions, making this update critical for investors tracking its financial performance and strategic direction.
Bionano Genomics (Nasdaq: BNGO) announced its participation at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., the company's president and CEO, will present a corporate overview on March 6th, 2023, at 1:30 pm ET. The presentation will be available via a live webcast accessible on Bionano’s Investors website.
Bionano Genomics announced that its OEM partner, Beijing Genome Precision Technology (BGPT), has received Class I registration approval from China’s National Medical Products Administration (NMPA) for DNA isolation and labeling kits. The approved reagents are intended for in vitro diagnostics in hematologic malignancies and will allow BGPT to sell optical genome mapping (OGM) reagents to independent clinical laboratories while pursuing approval for Bionano's Saphyr® system. This development is expected to facilitate sales and placements of Bionano's instruments and reagents in China, enhancing its market presence.
Bionano Genomics, Inc. (Nasdaq: BNGO) presented advancements in optical genome mapping (OGM) during the AGBT 2023 workshop, emphasizing its potential to replace traditional methods for structural variant (SV) detection. Collaborating with NVIDIA, they showcased a new compute solution for high-throughput OGM analysis. Key presentations highlighted OGM's effectiveness in identifying undetected SVs relevant to rare diseases. Additionally, Bionano launched the Innovator Research Grant to promote research utilizing OGM technology. These developments aim to enhance genome analysis resolution and sensitivity in clinical and translational research.
Bionano Genomics, Inc. (BNGO) held its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City, featuring key executives discussing growth strategies, financial goals, and product development. The event included panels with experts in optical genome mapping (OGM), focusing on its applications in cancer and genetic disease research. Bionano aims to enhance cytogenetic analysis through OGM, targeting segments like cell bioprocessing and cancer research. The company is working on product launches and strategies to increase OGM adoption, with a focus on regulatory approvals and reimbursement for OGM-based tests.